Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

April’s top stories: NIAID’s Phase II/IIb Zika vaccine trial, Boehringer’s nintedanib in Phase III trial

The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb clinical trial of a Zika vaccine, and Boehringer Ingelheim began patient enrolment in the Phase III PF-ILD trial of nintedanib to treat various progressive fibrosing lung diseases. Drug development-technology.com wraps up the key headlines from April.

Go Top